openPR Logo
Press release

Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Higher Mortality Rates by 2026

01-20-2022 07:35 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Trends Market Research

According to TMR, the Global Epidermal Growth Factor Receptor (EGFR) Inhibitors Market is accounted for $1.91 billion in 2017 and is expected to reach $4.96 billion by 2026 growing at a CAGR of 11.2% during the forecast period. Factors such as increasing special drug designation, proven efficacy of EGFR inhibitors and the growing prevalence of cancer indications are fuelling the market growth. However, prevent cell growth would be hindered by all participants receiving EGFR.

The Epidermal growth factor receptor (EGFR, also known as ErbB-1 or HER-1) inhibitors are medicines that bind to certain parts of the EGFR and slow down or stop cell growth. EGFR is a protein that is found on the surface of some cells that causes cells to divide when epidermal growth factor binds to it. EGFR is found at abnormally high levels in cancer cells, and EGFR activation appears to be important in tumour growth and progression. Some types of cancers show mutations in their EGFRs, which may cause unregulated cell division through continual or abnormal activation of the EGFR. EGFR inhibitors may be used in the treatment of cancers that are caused by EGFR up-regulation, such as non-small-cell lung cancer, pancreatic cancer, breast cancer, and colon cancer.

For more info, Get PDF at: https://www.trendsmarketresearch.com/report/sample/11419

Based on indication, the market is segmented into lung cancer, colorectal cancer, breast cancer, and others. Lung cancer is the leading cause of cancer-related death in both men and women in the United States, and the median 5-year survival rate for lung cancer is 5% worldwide.1 Lung cancer is divided into 2 major categories based on histological features: small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC), which constitute 15% and 85% of lung cancer cases, respectively. By Geography, North American region led the epidermal growth factor receptor inhibitors market. The growth of the epidermal growth factor receptor inhibitors market in North America can be attributed to factors such as the increasing prevalence of the various types of major cancer indications, heavy sales of approved therapeutics, and the presence of various patient programs from both the vendors and the governments in the region.

Some of the key players profiled in the Epidermal Growth Factor Receptor (EGFR) Inhibitors market include Amgen Inc, Bristol-Myers Squibb, Erbitux, F. Hoffmann-La Roche Ltd, Genentech, Inc, OSI Pharmaceuticals Inc, Tarceva and Vectibix.

Indications Covered:
• Breast Cancer
• Colorectal Cancer
• Lung Cancer
• Others Indications

Blocking Drugs Covered:
• Monoclonal Antibodies
• Tyrosine Kinase Inhibitors (TKI)

You can Buy This Report from Here @ https://www.trendsmarketresearch.com/checkout/11419/Single

Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa

What our report offers:
– Market share assessments for the regional and country level segments
– Strategic recommendations for the new entrants
– Market forecasts for a minimum of 9 years of all the mentioned segments, sub segments and the regional markets
– Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
– Strategic analysis: Drivers and Constraints, Product/Technology Analysis, Porter’s five forces analysis, SWOT analysis etc.
– Strategic recommendations in key business segments based on the market estimations
– Competitive landscaping mapping the key common trends
– Company profiling with detailed strategies, financials, and recent developments
– Supply chain trends mapping the latest technological advancements

Get Discount on This Report: https://www.trendsmarketresearch.com/report/discount/11419

Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the clients interest (Note: Depends of feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Address: One Vincent Square, Westminster, London SW1P 2PN, UK
Phone:+44-745-128-6161
Email: sales@trendsmarketresearch.com

Trends Market Research has the distinguished objective of providing the optimal quality market research reports to clients. Our market research studies by products, services, applications, technologies, end users, and market players for global, regional, and country level market segments, enable our clients to know more, see more, and do more, which further help answer the important questions you have about the industry. Our Research Analysts are eager to share their knowledge and assist you in making strategic decisions and to lead you company toward a greater endeavour. We bridge the gap between our clients and their clients by identifying and decoding just the target group, while generating leads with the highest accuracy.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Epidermal Growth Factor Receptor (EGFR) Inhibitors Market Higher Mortality Rates by 2026 here

News-ID: 2533054 • Views:

More Releases from Trends Market Research

Germany In Vitro Fertilization (IVF) Market size receive overwhelming hike in Re …
The Germany IVF market was valued at $398 million in 2018 and is estimated to reach $541 million by 2026, registering a CAGR of 3.9% during the analysis period. In vitro fertilization (IVF) is a process that includes fertilization of egg cells outside the body. It is one of the widely known infertility treatment across the clinical industry. The technique is based on assisted reproductive technology and is employed in the
Advanced Driver Assistance Systems (ADAS) Market Estimated size be driven size I …
Advanced driver assistance systems are intelligent systems which are installed in the vehicle to assist the driver with safe and comfortable driving experience. These systems are used to provide vital information such as traffic congestion level, suggested routes, blockage & closure of roads ahead, and others. In addition, ADAS is also used to analyze the fatigue and distraction of human driver and make precautionary alerts to make suggestions regarding same
UK Cold Chain Logistics Market Set size Surge Significantly During 2030
The UK cold chain logistics market size was valued at $4.55 billion in 2018 and is projected to reach $24.37 billion by 2026, registering a CAGR of 23.6% from 2019 to 2026. The meat, fish, and sea food segment accounted for the highest share in 2018 and is anticipated to exhibit remarkable growth rate during the forecast period. Adoption of cold chain logistics plays a crucial role in avoiding the wastage
Europe 5G Infrastructure Market size Reflect Impressive Growth Rate during 2030
The Europe 5G infrastructure market size was valued at $147.5 million in 2018 and is projected to reach $27.74 billion by 2026, growing at a CAGR of 96.2% from 2019 to 2026. 5G is fifth generation cellular technology, which consists of hardware component manufacturer, technology enablers, and telecom operators that facilitate 5G connections, operations, communication, supervision, and management of an enterprise network. 5G speed assures stronger connectivity, which creates seamless

All 5 Releases


More Releases for EGFR

EGFR Inhibitors Market to Reach USD 16 Billion by 2034
Targeting Lung Cancer with Precision: EGFR Inhibitors Market to Reach USD 16 Billion by 2034 The global burden of non-small cell lung cancer (NSCLC), the most prevalent form of lung cancer, continues to rise, and so does the demand for more targeted, effective, and personalized treatments. Epidermal Growth Factor Receptor (EGFR) inhibitors have emerged as a game-changing class of targeted therapies that address EGFR gene mutations-common drivers in NSCLC patients, especially
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market Growth 2025: Trends, Consu …
The EGFR non-small cell lung cancer (EGFR + NSCLC) market is estimated to be valued at USD 4.65 Bn in 2025 and is expected to reach USD 7.92 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.9% from 2025 to 2032. The Latest published market study on EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Market report provides an overview of the current market dynamics as well
EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Clinical Trials 2024: EMA, PDMA, …
(New York, United States) As per DelveInsight's assessment, globally, EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) pipeline constitutes 30+ key companies continuously working towards developing 30+ EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the
EGFR Non-Small Cell Lung Cancer Pipeline Report 2024
DelveInsight's, "EGFR Non-Small Cell Lung Cancer (EGFR + NSCLC) Pipeline Insights 2024" report provides comprehensive insights about 40+ EGFR Non-Small Cell Lung Cancer companies and 42+ pipeline drugs in the EGFR Non-Small Cell Lung Cancer pipeline landscape. It covers the EGFR Non-Small Cell Lung Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the EGFR Non-Small Cell Lung Cancer pipeline therapeutics assessment by product type, stage,
EGFR Mutation Test Market to Show Incredible Growth by 2027 | Novartis, Illumina
It shows how the COVID-19 health problem has affected a variety of companies. The COVID-19 epidemic and related lockdown countermeasures have wreaked havoc on several various segments of the economy; however, a few have seen growing demands. This EGFR Mutation Test market report's major objective is to forecast market growth from 2021 to 2027. A Market Report is the result of a data-driven strategy. It displays data in a visually
EGFR Mutation Test Market Estimated to Flourish by 2016 – 2024
Epidermal growth factor receptor (EGFR) is a type of protein, which is located on the surface of human body cells. Any mutation in EGFR gene can lead to various types of cancer. EGFR functions as a biomarker for non-small cell lung cancer (NSCLC) and due to the mutation of EGFR gene a person may suffer from cancer or may have a tumor growth. Tumors with genetically altered EGFR gene are